Cantley presenting latest cancer research at Distinguished Speaker Series

Since 1984, when he first discovered the signaling pathway phosphoinositide 3-kinase (PI3K), Lewis Cantley has made significant advances in cancer research. Cantley, a renowned cell biologist and biochemist and the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York, will present his latest work at the University of Illinois Cancer Center Distinguished Speaker Series at noon on Wednesday, March 31.

The author of more than 400 papers and 50 book chapters, Cantley, PhD, has been the recipient of numerous accolades, including membership in the American Academy of Arts and Sciences, the National Academy of Sciences, the Institute of Medicine of the National Academies, and the Europeans life sciences academy EMBO.

Cantley, who was named to his current position at Weill Cornell Medicine in 2012, is a graduate of West Virginia Wesleyan College (BS, Chemistry) and Cornell University (PhD, Biophysical Chemistry). He has also served as a professor at Tufts University and Harvard University, and was director of the Beth Israel Deaconess Cancer Center in Boston.

Registration is required for this virtual event.

Translate »